首页> 美国卫生研究院文献>Lippincott Williams Wilkins Open Access >Assessment of Corticosteroid-induced Osteonecrosis in Children Undergoing Chemotherapy for Acute Lymphoblastic Leukemia: A Report From the Japanese Childhood Cancer and Leukemia Study Group
【2h】

Assessment of Corticosteroid-induced Osteonecrosis in Children Undergoing Chemotherapy for Acute Lymphoblastic Leukemia: A Report From the Japanese Childhood Cancer and Leukemia Study Group

机译:接受糖皮质激素诱导的急性坏死性白血病化疗儿童骨坏死的评估:日本儿童癌症和白血病研究小组的报告

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Steroid-induced osteonecrosis (ON) is a challenging complication encountered during modern chemotherapy for childhood acute lymphoblastic leukemia (ALL). We retrospectively assessed the incidence of ON and its risk factors in a total of 1095 patients enrolled in 3 consecutive Japanese Children’s Cancer and Leukemia Study Group ALL studies (ALL941 [1994 to 2000], n=464; ALL2000 [2000 to 2004], n=305; and ALL2004 [2004 to 2010], n=326). ON was diagnosed in 16 patients, of whom 15 were symptomatic. The cumulative incidence of ON was 0.76% in ALL941, 0.35% in ALL2000, and 3.6% in ALL2004. The incidence of ON in ALL941/2000, in which only prednisolone was administered as a steroid, was significantly lower than that in ALL2004, in which dexamethasone was used as a partial substitute for prednisolone (P<0.01). In ALL2004, sex and age were significantly correlated with the incidence of ON (1.3% in boys vs. 6.7% in girls, P=0.0132; 0.42% for age <10 y vs. 15.6% for age ≥10 y, P<0.0001), suggesting that girls aged 10 years and above are at a greater risk of ON onset. These results indicate that the risk of ON should be considered when administering dexamethasone as part of ALL protocol treatment in girls aged 10 years and above.
机译:类固醇诱导的骨坏死(ON)是在现代化学疗法治疗儿童急性淋巴细胞白血病(ALL)时遇到的具有挑战性的并发症。我们回顾性评估了连续3项日本儿童癌症和白血病研究组(ALL941 [1994至2000],n = 464; ALL2000 [2000至2004],n)的1095名患者的ON发生率及其危险因素= 305; ALL2004 [2004至2010],n = 326)。 16例患者被诊断为ON,其中15例是有症状的。 ON的累积发生率在ALL941中为0.76%,在ALL2000中为0.35%,在ALL2004中为3.6%。在仅使用泼尼松龙作为类固醇的ALL941 / 2000中,ON的发生率明显低于使用地塞米松作为泼尼松龙的部分替代品的ALL2004(P <0.01)。在ALL2004中,性别和年龄与ON的发生率显着相关(男孩为1.3%,女孩为6.7%,P = 0.0132;年龄<10岁的为0.42%,年龄≥10岁的为15.6%,P <0.0001 ),表明10岁及以上的女孩罹患ON的风险更大。这些结果表明,在10岁及以上的女孩中,将地塞米松作为ALL方案治疗的一部分时,应考虑ON的风险。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号